Loading...
XNASADIL
Market cap6mUSD
Dec 26, Last price  
1.05USD
1D
0.00%
1Q
3.96%
IPO
-98.95%
Name

Adial Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:ADIL chart
P/E
P/S
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
49.56%
Rev. gr., 5y
%
Revenues
0k
Net income
-7m
L-45.00%
-817,993-420,200-1,139,456-11,631,378-8,591,429-10,860,495-19,423,326-12,731,416-7,001,890
CFO
-7m
L-39.15%
-465,222-274,384-494,862-2,498,387-6,338,614-7,633,161-11,949,429-11,185,985-6,806,809
Earnings
Mar 31, 2025

Profile

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
IPO date
Jul 27, 2018
Employees
16
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
6,889
13,378
17,795
Unusual Expense (Income)
NOPBT
(6,889)
(13,378)
(17,795)
NOPBT Margin
Operating Taxes
(502)
(94)
Tax Rate
NOPAT
(6,889)
(13,377)
(17,701)
Net income
(7,002)
-45.00%
(12,731)
-34.45%
(19,423)
78.84%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,132
9,126
11,750
BB yield
-155.94%
-4,238.11%
-23.41%
Debt
Debt current
57
50
Long-term debt
358
464
Deferred revenue
Other long-term liabilities
(437)
492
1,014
Net debt
(4,361)
(2,986)
(4,934)
Cash flow
Cash from operating activities
(6,807)
(11,186)
(11,949)
CAPEX
(65)
Cash from investing activities
1,500
(34)
Cash from financing activities
4,132
9,126
13,645
FCF
(6,644)
(13,317)
(18,006)
Balance
Cash
2,827
4,002
6,062
Long term investments
1,534
(601)
(614)
Excess cash
4,361
3,401
5,448
Stockholders' equity
(68,796)
(63,648)
(50,922)
Invested Capital
72,879
67,624
55,701
ROIC
ROCE
EV
Common stock shares outstanding
1,425
40
744
Price
1.86
-65.40%
5.38
-92.04%
67.50
58.82%
Market cap
2,650
1,130.65%
215
-99.57%
50,190
136.88%
EV
(1,711)
(2,771)
45,255
EBITDA
(6,888)
(13,317)
(17,740)
EV/EBITDA
0.25
0.21
Interest
585
Interest/NOPBT